Semaglutide Shows Potential for Nerve Regeneration in Children with MC4R-Related Obesity
Key Insights
A case report indicates that semaglutide treatment may promote nerve regeneration in children with monogenic obesity (search) caused by melanocortin-4 receptor (search) (MC4R (search)) mutations.
The study observed increases in corneal nerve fiber density and length in two siblings treated with semaglutide for six months.
Nerve regeneration occurred independently of significant changes in weight, HbA1C, or lipid levels, suggesting a direct effect of GLP-1 (search) therapy.
Two siblings with monogenic obesity (search) resulting from melanocortin-4 receptor (search) (MC4R (search)) mutations showed nerve regeneration following six months of treatment with semaglutide, a glucagon-like peptide-1 (GLP-1 (search)) receptor agonist. The findings, reported in Frontiers in Endocrinology, suggest a potential novel application for GLP-1 agonists in addressing neurological complications associated with genetic obesity.
Background
Monogenic obesity (search), often caused by MC4R (search) mutations, leads to impaired satiety and hyperphagia (search) in early childhood, resulting in severe, early-onset obesity. Traditional lifestyle interventions and even bariatric surgery have shown limited long-term benefits in these patients. GLP-1 (search) receptor agonists have demonstrated beneficial effects on weight, blood pressure, and lipids, potentially impacting neuronal health by decreasing reactive oxygen species and inflammation.
Study Details and Results
Researchers assessed corneal nerve regeneration using corneal confocal microscopy in two siblings (a 10-year-old boy and an 8-year-old girl) with a heterozygous missense variant in the MC4R (search) gene. The siblings were treated with semaglutide at 0.5 mg weekly for one month, followed by 1.0 mg weekly for five months. Baseline HbA1C values were 5.8% and 5.6%, respectively. Both children exhibited intense hyperphagia (search), impaired satiety, and severe obesity.
After six months of semaglutide treatment, corneal confocal microscopy revealed small nerve fiber regeneration. Specifically, the brother showed a 13.9% increase in corneal nerve fiber density, a 110.2% increase in corneal nerve branch density, and a 21.5% increase in corneal nerve fiber length. The sister showed corresponding increases of 14.7%, 58.7%, and 44.0%, respectively. Notably, these improvements occurred without major changes in weight, HbA1C, or lipid levels.
Potential Mechanisms
The researchers hypothesize that the nerve regeneration observed may be independent of weight and glycemic control. They suggest that GLP-1 (search) therapies activate sirtuin 1, which has been associated with nerve regeneration. Additionally, GLP-1 receptors are expressed in the dorsal root ganglion and peripheral nerves. Previous studies have shown that GLP-1 treatment can lead to intraepidermal nerve fiber regeneration in animal models of type 1 diabetes (search) without affecting weight or glucose levels.
Clinical Implications
These findings suggest that semaglutide may offer a neuroprotective effect in individuals with MC4R (search) mutations, potentially mitigating subclinical neurodegeneration associated with this genetic condition. Further research is warranted to explore the mechanisms underlying this nerve regeneration and to assess the long-term clinical benefits of GLP-1 (search) therapy in this patient population. The study highlights the potential for GLP-1 agonists to impact neuronal health beyond their established effects on weight and metabolic parameters.